Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
DARRICK Albert CARTER · PAI LIFE SCIENCES, INC. · 2020 · $556,615 — PROJECT SUMMARY A central mechanism of tumor drug resistance is the maintenance of tight junctions between malignant cells preventing penetration of molecules into the tumor microenvironment. We have generated junction openers (“JO”) that are small proteins that bind to desmoglein 2 (DSG2), a juncti…
Huan Xie · TEXAS SOUTHERN UNIVERSITY · 2020 · $226,261 — PROJECT SUMMARY Prostate cancer (PCa) is the second leading cause of cancer death in the United States among men and it is more common in African American males. Despite initial good responses to androgen deprivation or anti- androgen drugs, tumors invariably recur and develop into lethal castration…
JAY W HEINECKE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $262,515 — We propose to investigate the structural basis of the interaction of LCAT with HDL. We will complement these in vitro studies with analyses of HDLs of subjects with LCAT deficiency. Because these patients have very low HDL-C levels but apparently little increased cardiovascular risk, their HDL might…
TIMOTHY J. WILKIN · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $1,017,165 — Clinical Trials Program Project Summary/Abstract The overall goal of the proposal is to advance prevention interventions for HPV-associated cancers occurring among men and women living with HIV in Latin America and the Caribbean (LAC). We are focusing on prevention of two HPV-associated cancers, or…
YONG ZHU · YALE UNIVERSITY · 2019 · $182,156 — Abstract The goal of the proposed study is to demonstrate the viability of a novel Piwi-interacting RNA (piRNA)-based therapeutic strategy for the treatment of hepatocellular carcinoma (HCC). piRNAs are an abundant class of small (26-31 nt) non-coding RNAs with approximately 23,000 known human membe…
Huang Chiao Huang · UNIV OF MARYLAND, COLLEGE PARK · 2019 · $249,000 — DESCRIPTION (provided by applicant): It is increasingly evident that rationally designed combination therapies impacting multiple targets will most likely to improve outcomes in patients with glioblastoma (GBM). However, the selective delivery of multiple regimens to the right place, at the right ti…
Andrei Maiseyeu · CASE WESTERN RESERVE UNIVERSITY · 2019 · $396,250 — Project Summary Hyperglycemia is the hallmark of type 2 diabetes (T2D) and accelerates the development of atherosclerosis, which, in turn, precedes the development of major cardiovascular complications. In people with T2D, cardiovascular disease significantly contributes to mortality, accounting fo…
Alexander Komin · JOHNS HOPKINS UNIVERSITY · 2019 · $35,908 — Project Summary The drug therapies against the central nervous system (CNS) disorders, such as brain cancer, stroke and Alzheimer's disease, are very limited because of the challenges associated with delivering drugs across the blood-brain barrier (BBB) into the brain. There is a need to develop nov…
Subhash C. Chauhan · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2019 · $140,790 — The long-term goal of the proposed research proposal is to develop a targeted paclitaxel nanotherapy that can be used for the treatment of pancreatic cancer (PanCa) in combination with Gemcitabine (GEM). Although many conventional and combinational chemotherapies exist to treat PanCa, significant si…
Ning Fang · GEORGIA STATE UNIVERSITY · 2019 · $301,325 — DESCRIPTION (provided by applicant): Viruses, drug delivery vectors, and other external particles exhibit a variety of complex behaviors on and in the cell membrane that are reflective of their physical and chemical properties, including size, shape, charge and the availability of membrane rece…
Mark Bathe · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2019 · $193,750 — PROJECT SUMMARY Targeted delivery of therapeutic gene editing CRISPR ribonucleoprotein (RNP) complexes to cells offers major opportunities for next-generation therapies, however, realization of this goal requires a vehicle to protect and direct CRISPR RNPs to their targeted cells and tissues. Curren…
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2019 · $679,764 — Project Summary Hemophilia is a genetic disorder defined by either an inadequate supply or an inactive blood clotting factor. The two most common forms are hemophilia A and B, caused by genetic defects in clotting factors VIII and IX, respectively. Both are X-linked recessive disorders characterize…
THOMAS Elliott VAN DYKE · ADA FORSYTH INSTITUTE, INC. · 2019 · $486,638 — Project Summary Uncontrolled inflammation is a major impediment to tissue engineering, regeneration and reconstruction of both diseased and injured tissues resulting in further tissue injury, tissue scarring and fibrosis. Stem cell activity is disrupted by persistent signals promoting inflammation, …
Lbachir BenMohamed · UNIVERSITY OF CALIFORNIA-IRVINE · 2019 · $188,938 — PROJECT SUMMARY/ABSTRACT A staggering number of individuals—over 3 billion worldwide—are currently infected with herpes simplex virus type 1 (HSV-1), which causes frequent, and often lifelong, bouts of recurrent corneal herpetic disease. This potentially blinding disease is a result of corneal re-i…
DARRICK Albert CARTER · PAI LIFE SCIENCES, INC. · 2019 · $720,945 — PROJECT SUMMARY A central mechanism of tumor drug resistance is the maintenance of tight junctions between malignant cells preventing penetration of molecules into the tumor microenvironment. We have generated junction openers (“JO”) that are small proteins that bind to desmoglein 2 (DSG2), a juncti…
Zahi A. Fayad · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2019 · $816,219 — SUMMARY Atherosclerotic plaque regression as a result of lipid-lowering treatment has been limited at best, with coronary artery disease (CAD) related event rates remaining unacceptably high. In this application, we propose that targeted immunomodulation of macrophages will resolve plaque inflamma…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2019 · $364,500 — Project Summary Co-delivery of Cas9 mRNA and targeted sgRNA is a promising strategy to achieve CRISPR/Cas gene editing in vivo with improved safety. Although great advances have been made in the delivery of short RNAs (siRNA, miRNA), the ideal chemical and formulation composition is largely unknown …
Laura A Hansen · CREIGHTON UNIVERSITY · 2019 · $176,997 — ABSTRACT Nonmelanoma skin cancer is the most common cancer in the USA, occurring in 1 of 5 Americans during their lifetime. The incidence of skin cancer is rising as well, due to increased exposure to sunlight and other sources of ultraviolet (UV) irradiation, the primary cause of approximately 90% …
Shyam Sunder Chaurasia · UNIVERSITY OF MISSOURI-COLUMBIA · 2019 · $193,475 — PROJECT SUMMARY Chemical weapons were used in world wars, and more recently in Iraq and Syria. Acrolein, a volatile aldehyde, used during World War I caused severe problems in eye, skin and lungs in addition to many casualties. At present, there are no countermeasures available that can prevent, imp…
Kenneth W Witwer · JOHNS HOPKINS UNIVERSITY · 2019 · $457,682 — DESCRIPTION (provided by applicant): Combined antiretroviral therapy (cART) has dramatically changed the HIV epidemic, prolonging life and reducing morbidities. Nevertheless, a wide range of non-AIDS conditions continue to afflict people living with HIV, including cancers as well as cardiovascu…